Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$77.69 USD

77.69
2,215,309

-0.92 (-1.17%)

Updated Aug 7, 2025 03:45 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Zacks Equity Research

Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.

Zacks Equity Research

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

Zacks Equity Research

IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase

by Zacks Equity Research

Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.

Zacks Equity Research

Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up

by Zacks Equity Research

Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.

Zacks Equity Research

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.

Zacks Equity Research

Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Zacks Equity Research

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Zacks Equity Research

Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates

by Zacks Equity Research

Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.

Zacks Equity Research

ALC or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALC vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong

by Zacks Equity Research

DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Zacks Equity Research

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.

Zacks Equity Research

Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Zacks Equity Research

Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.

Zacks Equity Research

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

Zacks Equity Research

West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

Zacks Equity Research

Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.

Zacks Equity Research

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.

Zacks Equity Research

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance

by Zacks Equity Research

Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.

Zacks Equity Research

CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.

Zacks Equity Research

Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.64% and 4.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Philips' (PHG) Q1 Earnings Jump Y/Y on Strong Top-Line Growth

by Zacks Equity Research

Philips' (PHG) first-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More

by Urmimala Biswas

MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.

Zacks Equity Research

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.